A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects with Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate Lung01)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512368-79-00

Enrollment

Registered

2024-07-12

Start date

2022-10-10

Completion date

Unknown

Last updated

2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Brief summary

Objective response rate (ORR), defined as the proportion of subjects with a BOR of confirmed CR or confirmed PR assessed by blinded independent central review (BICR) based on RECIST v1.1.

Interventions

DRUGIfinatamab deruxtecan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate (ORR), defined as the proportion of subjects with a BOR of confirmed CR or confirmed PR assessed by blinded independent central review (BICR) based on RECIST v1.1.	—

Countries

France, Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026